Humoral Effect of a B-Cell Tumor on the Bone Marrow Multipotent Mesenchymal Stromal Cells

Petinati, Nataliya; Bigildeev, Alexey; Karpenko, Dmitriy; Sats, Natalia; Kapranov, Nikolay; Davydova, Yulia; Fastova, E A; Magomedova, Aminat; Кравченко, С К; Arapidi, Georgij; Rusanova, Maria I; Lagarkova, Maria A.; Drize, Nina; Савченко, В Г

doi:10.1134/s0006297921020097

Cited by 9 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These differences may be based on different pathogenesis and different signaling pathways, as well as the molecular mechanisms involved. We have conducted a study that suggested changes in the properties of multipotent mesenchymal stem cells (MMSCs) under the influence of cytokines produced by tumor cells [30,31]. However, further studies are needed to confirm the above.…”

Section: Discussionmentioning

confidence: 99%

Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Efficacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol

Magomedova,

Kravchenko,

Misyurina

et al. 2022

Arch Clin Trials

View full text Add to dashboard Cite

Background: NHL-BFM-90 chemotherapy is highly effective in pediatric aggressive B-cell lymphomas. Purpose: To evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DAEPOCH-21 programs in adult patients with de novo DLBCL. Patients and methods: Inclusion criteria: newly diagnosed DLBCL (NOS), no previous chemotherapy, 2 or more signs of poor prognosis, age 18-60. The protocol included 140 patients from 13 medical centers in Russia: R-DA-EPOCH-21 – 33; R-DAEPOCH-21+auto-HSCT - 29; R-mNHL-BFM-90 - 33; R-mNHL-BFM-90+ auto-HSCT -35 patients. R-DA-EPOCH-21 branch: 6 courses were performed. If CR was not achieved, 2 courses of R-DHAP were performed ± auto-HSCT. Branch R-mNHL-BFM-90 included 6 cycles: RA-RB-RA-RB-RA-RB. If CR was not achieved, 2 courses of R-DHAP ± auto-HSCTResults: Of 62 patients on R-DA-EPOCH-21±auto-HSCT, CR was achieved in 36 (58.1%) patients, PR was achieved in 14 (22.6%) patients, progression was reported in 6 (9.7%) patients, 3 (4.8%) patients had died, and treatment continued in 3 (4.8%) patients. Of 68 patients on R-mNHL-BFM-90±autoHSCT CR was achieved in 63 (92.7%) patients, PR was achieved in 2 (2.9%) patients, progression was not reported, 2 (2.9%) patients had died, and treatment continued in 1 (1.5%) patient. The 4-year OS of patients in the high-risk group 94% on R-mNHL-BFM-90 therapy, 81% on R-DA-EPOCH-21 therapy;. the 4-year EFS of patients in the high-risk group was 78% and 43%, respectively (p = 0.0004). Conclusion: R-mNHL-BFM-90 program is highly effective in de novo DLBCL NOS adult patients; toxicity is acceptable.

show abstract

Section: Discussionmentioning

confidence: 99%

Multicenter Randomized Controlled (Comparative) Open Prospective Study to Evaluate The Efficacy of The R-DA-EPOCH-21 And R-mNHL-BFM-90 ± Autologous Hematopoietic Stem Cell Transplantation Programs in Untreated Patients With De Novo Diffuse B-Cell Large Cell Lymphoma With Signs of Poor Prognosis - DLBCL-2015 Protocol

Magomedova,

Kravchenko,

Misyurina

et al. 2022

Arch Clin Trials

View full text Add to dashboard Cite

show abstract

“…In particular, it proved that Hodgkin's lymphoma cells express IL-1, IL-5, IL-9, TNFα, M-CSF, etc., which are responsible for the enhancement of the cellular response and fibrosis observed in HL tissues [21]. In addition, the effect of blood plasma of a patient with DLBCL on the properties of mesenchymal hematopoietic stem cells through cytokines and proteins secreted by tumor cells is proven [22]. Therefore, it assumed that tumor cells of de novo and secondary DLBCL secrete "their" cytokines, and it causes different clinical manifestations.…”

Section: Exclusive/predominant Retroperitoneal Localizationmentioning

confidence: 99%

Clinical and Laboratory Data Which Are Not Typical of De Novo Diffuse Large B-Cell Lymphoma

Magomedova¹,

Misyurina²,

Кравченко³

et al. 2022

Lymphoma

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of diseases of the lymphatic system, which is represented by de novo and secondary tumors resulting from the transformation of indolent lymphomas. In the absence of a long history of the disease at the stage of histological transformation (HT), it is difficult to distinguish between de novo and secondary diffuse large B-cell lymphoma. According to the data of a randomized study, we obtained clinical and laboratory data that are not typical for de novo diffuse large B-cell lymphoma. These include exclusive, predominant retroperitoneal localization, compression of the ureters/kidneys with or without the development of acute renal failure (ARF), unilateral lymphostasis of the leg due to compression of the inguinal, iliac lymph nodes by the conglomerate, intratumor in the central nervous system (CNS) at the onset/relapse/progression of the disease, discordant bone marrow involvement, blood involvement, paraprotein secretion.

show abstract

“…Thus, the influence of individual elements on small groups is checked. Early versions of algorithm was applied previously [1,2]. Results: An algorithm was developed and tested in Python v.3.7 in Microsoft Windows.…”

mentioning

confidence: 99%

Multidimensional analysis, dimension reduction, categorization with statistical approach – stability and reproducibility

2022

The Thirteenth International Multiconference

View full text Add to dashboard Cite

Humoral Effect of a B-Cell Tumor on the Bone Marrow Multipotent Mesenchymal Stromal Cells

Cited by 9 publications

References 19 publications

Clinical and Laboratory Data Which Are Not Typical of De Novo Diffuse Large B-Cell Lymphoma

Multidimensional analysis, dimension reduction, categorization with statistical approach – stability and reproducibility

Contact Info

Product

Resources

About